Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most mechanistic and grapefruit/CYP3A4 interaction concepts are supported, but several claims about wine/bleeding, and dose limits expressed as manufacturer guidelines are unsupported or not supported by the provided label excerpts. Additionally, some adverse-effect associations are over-attributed to 'increased atorvastatin levels' beyond what the provided sections state.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin.
Label provided describes LIPITOR as an HMG-CoA reductase inhibitor (statin class implied by provided mechanism section 12.1).
LIPITOR works by inhibiting HMG-CoA reductase, converting HMG-CoA to mevalonate, a precursor of sterols including cholesterol.
12.1 Mechanism of Action: “selective, competitive inhibitor of HMG-CoA reductase… converts… to mevalonate… including cholesterol.”
LIPITOR lowers LDL-C (LDL or LDL-cholesterol).
12.1: “LIPITOR reduces total-C, LDL-C…” and “Clinical studies… elevated… LDL-cholesterol…”; also animal model/plasma cholesterol effects.
Grapefruit juice contains components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin, especially with excessive consumption (>1.2 liters/day).
7.2 Grapefruit Juice: “Contains… components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).”
Atorvastatin is metabolized by CYP3A4.
7.1 Strong Inhibitors of CYP 3A4: “LIPITOR is metabolized by cytochrome P450 3A4.”
Concomitant administration of LIPITOR with strong inhibitors of CYP3A4 can lead to increases in plasma concentrations of atorvastatin.
7.1: “Concomitant administration… with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin.”
Patients taking LIPITOR may experience muscle pain/aches or weakness as part of myopathy, and rare rhabdomyolysis has been reported post-approval.
5.1 Skeletal Muscle: “Atorvastatin… occasionally causes myopathy, defined as muscle aches or muscle weakness…”; and “Rare cases of rhabdomyolysis with acute renal failure…”; 6.2/7 postmarketing: includes rhabdomyolysis.
Atorvastatin levels (plasma concentrations) may increase with CYP3A4 inhibition.
7.1 and 7.2: both describe increased plasma concentrations with CYP3A4 inhibition.
Increased atorvastatin plasma concentrations from CYP3A4 inhibition can increase the risk of myopathy/rhabdomyolysis in the context of interacting agents (i.e., higher risk of skeletal muscle effects).
5.1: “The concomitant use of higher doses… with certain drugs such as… strong CYP3A4 inhibitors… increases the risk of myopathy/rhabdomyolysis.”
Unsupported Statements
Grapefruit and its juice contain furanocoumarin.
7.2 provided excerpt states grapefruit juice components inhibit CYP3A4 but does not state they are furanocoumarin.
Furanocoumarin can inhibit the enzyme CYP3A4.
No labeling excerpt provided supports the specific statement that furanocoumarin inhibits CYP3A4.
Patients taking Lipitor may experience muscle pain as an adverse effect associated with increased atorvastatin levels.
Label supports that myopathy includes muscle aches/weakness and that CYP3A4 inhibitor coadministration increases plasma concentrations and increases risk of myopathy/rhabdomyolysis, but the provided excerpts do not explicitly link 'muscle pain' to 'increased atorvastatin levels' as the direct stated mechanism for this adverse effect.
Patients taking Lipitor may experience liver damage as an adverse effect associated with increased atorvastatin levels.
5.2/6.2 discuss biochemical liver function abnormalities and hepatic failure in postmarketing, but do not state that liver damage is specifically due to increased atorvastatin levels.
Patients taking Lipitor may have an increased risk of bleeding as an adverse effect associated with increased atorvastatin levels.
No provided label excerpt mentions bleeding risk or a bleeding adverse effect.
According to the manufacturer's guidelines, patients taking Lipitor should avoid products that contain furanocoumarin.
Provided label excerpt 7.2 does not mention furanocoumarin avoidance.
A study reported in the Journal of Clinical Pharmacology found that moderate wine consumption (1-2 glasses per day) did not significantly affect levels of atorvastatin in the bloodstream.
No labeling excerpt provided includes wine studies or this claim.
A study reported in the Journal of Clinical Pharmacology stated that patients who consumed more than 2 glasses of wine per day may experience increased levels of atorvastatin.
No labeling excerpt provided includes wine studies or this claim.
The recommended limit of wine consumption on Lipitor is 1-2 glasses per day.
No provided label excerpt provides a wine consumption limit.
Moderate wine consumption may not significantly affect the levels of atorvastatin in the bloodstream.
No provided label excerpt addresses wine and atorvastatin plasma levels.
Patients taking Lipitor may have increased risk of adverse effects if they are heavy wine consumers.
No provided label excerpt connects wine intake to increased atorvastatin exposure or adverse-effect risk.
Lipitor should be avoided with medications that interact with grapefruit, including certain antibiotics and blood thinners.
The provided label excerpt lists strong CYP3A4 inhibitors (examples: clarithromycin, HIV protease inhibitors, itraconazole). It does not mention 'blood thinners' or antibiotics specifically as a grapefruit interaction category, nor does it use the phrase 'interact with grapefruit' as a label-defined category.
Contradictions
Important Omissions
The label excerpt for grapefruit specifies that the interaction is especially with excessive grapefruit juice consumption (>1.2 liters/day), and does not provide a simple categorical avoidance statement in the provided text.
Importance:
Moderate
The label excerpts provided do not support any wine-related counseling/limits; omitting the absence of such information could lead to overconfidence in wine dosing guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about wine consumption limits and bleeding risk could mislead patient counseling. Over-specific causal framing ('adverse effects associated with increased atorvastatin levels') is not fully supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims (wine limits, furanocoumarin content, bleeding risk, and 'avoid furanocoumarin products') are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or revise unsupported specifics (furanocoumarin/vitamin-specific avoidance, all wine/plasma-level study claims, bleeding risk, and the universal avoidance/dose-limit phrasing). Keep to label-supported statements: grapefruit juice inhibits CYP3A4 and can increase atorvastatin concentrations especially with excessive intake; LIPITOR is metabolized by CYP3A4; strong CYP3A4 inhibitors increase plasma concentrations and increase risk of myopathy/rhabdomyolysis; liver function monitoring recommendations and risk statements should not be causally tied to increased atorvastatin levels unless explicitly stated in the label.